You Position: Home > Paper

CLINICAL OBSERVATION OF 20 CHRONIC MYELOGENOUS LEUKEMIA WITH GLEEVEC

( views:436, downloads:8 )
Author:
No author available
Journal Title:
JOURNAL OF LEUKEMIA & LYMPHOMA
Issue:
2
DOI:
10.3760/cma.j.issn.1009-9921.2004.02.001
Key Word:
格列卫;慢性白血病;髓系

Abstract: 目的:评价格列卫治疗慢性粒细胞白血病(CML)的效果和不良副作用.方法:CML慢性期(CP)患者口服格列卫400mg/d.CML加速期、急变期(BC)患者口服格列卫400mg~600mg/d.结果:11例CML-CP患者均取得血液学完全缓解(HCR).9例CML-AP和CML-BC患者4例取得HCR(37%).7例CML-CP患者在3个月~6个月内4例取得遗传学完全缓解(56%).CML-CP患者Ⅲ级白细胞(WBC)减少1例,血小板(BPC)减少2例.CML-AP和CML-BC患者,4例发生Ⅲ级~Ⅳ级WBC减少和BPC减少.而非血液学不良副作用,无Ⅲ级或Ⅳ级以上的毒副作用.结论:格列卫治疗CML-CP具有较高的HCR和细胞遗传学反应,CML-BC患者亦可取得较好的血液学反应.格列卫不良副作用发生率低,尤其CML-CP患者为安全,而CML-AP和CML-BC患者治疗期间,需加强支持治疗.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn